Acelrx announces an investigator-initiated study of dsuvia® for use in same-day total joint replacement

Hayward, calif., may 6, 2021 /prnewswire/ -- acelrx pharmaceuticals, inc. (nasdaq: acrx), (acelrx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced an investigator-initiated study to be conducted at the core institute specialty hospital in phoenix, arizona by the musculoskeletal orthopedic research and education (more) foundation evaluating the perioperative use of dsuvia (sufentanil sublingual tablet 30 mcg) for patients undergoing hip or knee replacement as a same-day surgical procedure.
ACRX Ratings Summary
ACRX Quant Ranking